Trends in clinical trials on bone regeneration in dentistry—towards an innovative development in dental implant treatment

Yoichi Yamada,a,b Sayaka Nakamura-Yamada,a Michihide Miki,a Yasushi Nakajima,a & Shunsuke Baba,a

a Department of Oral Implantology, Osaka Dental University, Osaka, Japan
b Department of Infectious Diseases and Applied Immunology, IMSUT Hospital, Institute of Medical Science, University of Tokyo, Tokyo, Japan

Corresponding author:

Dr. Yoichi Yamada
Osaka Dental University
1-5-17, Otemae Chuo-ku
Osaka
540-0008 Japan

yamada-yo@cc.osaka-dent.ac.jp


Abstract

Objective
The aim of this study was to assess the global trends in clinical trials on bone regeneration in dental implantology.

Materials and methods
An electronic search for clinical studies was conducted via the ClinicalTrials.gov database. The search strategy used the following terms: “bone regeneration” AND “oral,” and “bone regeneration” AND “dental”. Furthermore, the selected clinical studies were resurveyed using “bone regeneration” AND “dental implant,” and “bone regeneration” AND “oral” AND “implant” for further analysis.

Results
We selected 181 clinical studies related to the field of bone regeneration in dentistry from ClinicalTrials.gov. The selected studies were conducted in 27 countries from 2001 to the present, and the total number of studies has been increasing since 2011. Analysis of the clinical stage revealed a higher ratio (55.6%) of early study phases (early phase 1, phase 1, phase 1/2 and phase 2), but the periodontal field of application appeared more mature, having more phase 4 trials. Regarding the bone regeneration methods for dental implantology, the major technique examined in interventional clinical trials was guided bone regeneration, followed by alveolar ridge preservation, and sinus floor elevation. Various grafting materials, such as autografts, allografts, xenografts, alloplasts and barrier membranes, were examined to determine clinical efficacy. Combinations of these materials were more frequently used.

Conclusion
Our analysis of the clinical trials registered on the ClinicalTrials.gov database indicated the global clinical trends in bone regeneration techniques in dentistry. The randomized clinical trials of guided bone regeneration technique using combination of different bone grafts materials is conducted the most in dental implantology. These findings could be useful for development of an innovative therapy for bone regeneration.

Keywords: Bone regeneration; clinical trials; ClinicalTrials.gov; dental implants; regenerative medicine.
Introduction

A clinical trial is a study in humans that assesses safety and effectiveness of a new treatment. It is essential to develop new treatment for therapeutic use. It is clearly crucial to conduct clinical trials and log the relevant information on a database for development of novel medicine. During the 1990s, clinical trial registration was strongly promoted in biomedical research, with the aim of documenting the existence of all trials and eliminating publication bias. The International Committee of Medical Journal Editors required registration of all trials starting enrollment after July 1, 2005, and of ongoing clinical trials that began enrolling patients before that date. The World Health Organization declared support for clinical trial registration and in 2006 launched the WHO International Clinical Trials Registry Platform (ICTRP). The Clinical Trials Search Portal provides access to a central database containing the trial registration datasets. Currently, there are 17 data providers of the ICTRP Search Portal, including ClinicalTrials.gov, the EU Clinical Trials Register, the ISRCTN registry, the Japan Primary Registries Network, the Australian New Zealand Clinical Trials Registry, the Brazilian Clinical Trials Registry and the Chinese Clinical Trial Register (https://www.who.int/ictrp/search/data_providers/en/).

ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world and is the world’s largest clinical trial registration database. It is hosted by the National Library of Medicine at the National Institutes of Health in collaboration with the U.S. Food and Drug Administration. It explores 321,732 research studies in 209 countries and provides information about target diseases, sponsors, principal investigators, planned schedules and protocols, and enrollment. Moreover, since the database provides comprehensive information on the content of the planned clinical trials, one can perform various targeted analyses by extracting and tagging attribute data from each clinical study plan.

Alveolar bone loss is often caused by trauma, pathology, chronic or acute infections, severe periodontitis, and loss of mechanical function after tooth extraction or tooth loss. Since the overall alveolar changes after tooth extraction may compromise prosthetic rehabilitations using tooth-supported fixed or removable prostheses, as well as implant-supported prostheses, adequate quality and quantity of bone regeneration are required, especially in the field of implant dentistry. Various materials and surgical treatments have been developed, but a definitive bone regeneration technique is not yet established. To the best of our knowledge, there are no scientific reports that have comprehensively analyzed and examined the clinical research trends in bone regeneration in dental implant treatment.

In this article, the focus was on bone regeneration for an innovative development in dental implant treatment based on the clinical trials registration database. Since ClinicalTrials.gov is the largest clinical trial registration database in the world and is one of the best designed database providers for aggregation and analysis, we chose it to obtain the data for analysis. In this concise review, we first surveyed country, start year and clinical stage of clinical studies on bone regeneration in dentistry to identify global translational trends and followed this with analysis of the details about clinical trials in dental implantology. We aimed to establish global translational trends, which have thus far been difficult to interpret. The results of this study could be useful to learn of the development of new techniques in dental implantology.

Materials and methods

In this review, an extensive electronic search for clinical studies was conducted via the ClinicalTrials.gov database. The last search was updated on Nov. 11, 2019. Medical Subject Headings, combined with free words, was used to identify the search terms. The following search terms: “bone regeneration” AND “oral,” and “bone regeneration” AND “dental” were used for analysis by country, start year and clinical stage of the clinical studies. In this survey, we excluded duplicate studies and in vitro or preclinical studies using human subjects. In clinical stage analysis, the studies that were described as “not applicable” in the database were excluded. Furthermore, the selected clinical studies were resurveyed using “bone regeneration” AND “oral implant,” and “bone regeneration” AND “oral” AND “implant.” We excluded studies that were not related to bone regeneration by reading the descriptions of the individual studies.
Trends in clinical trials on bone regeneration

Fig. 1

Fig. 2

Completed
Withdrawn
Terminated
Active, not recruiting
Recruiting
Not yet recruiting
Enrolling by invitation
Unknown status
Results

We first surveyed ClinicalTrials.gov to identify translational trends in bone regeneration in dentistry. Initially, 181 studies were selected through a primary database search. After excluding duplicate studies, 144 studies remained. We excluded in vitro or preclinical studies using human subjects by carefully reading the descriptions of the individual studies, and 142 studies were used for their content for analysis. First, we classified the entire list of clinical studies on bone regeneration in dentistry by country (Fig. 1). The selected clinical studies were conducted in 27 countries, and the major country was the U.S. (32 studies), followed by Egypt (24 studies), Brazil (10 studies), India (10 studies), and Italy (10 studies).

In order to analyze the clinical research trends regarding bone regeneration in dentistry, the selected studies were sorted by start year (Fig. 2). This analysis showed that bone regeneration therapy was performed in dentistry from 2001 to the present. The first study was a clinical trial on periodontal tissue regeneration using fibroblast growth factor-2 conducted in Japan. The total number of studies has been increasing since 2011. The clinical studies were classified according to their current status. Some studies were withdrawn and the reasons given were the following “Principal investigator and sponsor did not reach an agreement,” “Lack of pediatric recruitment ability,” “Administrative changes precluded enrollment,” and “It was not approved by IRB [institutional review board].”

To determine progress in testing novel methods of bone regeneration in dentistry, the clinical stage was analyzed (Fig. 3). Among the selected studies, 79 studies were not applicable. Early phase 1, phase 1, phase 1/2 and phase 2 studies made up 55.6% of bone regeneration studies in dentistry. There were 17 phase 4 clinical trials, 9 of which were conducted in order to evaluate the efficacy of various products in the treatment of periodontal bone defects. The products...
used in periodontal treatment were as follows: atorvastatin gel, biological amniotic membrane, rosuvastatin, decalcified freeze-dried bone allograft and cerabone bone (botiss biomaterials), alendronate, simvastatin gel, amnion–chorion allograft membrane, and biphasic calcium phosphate (Straumann BoneCeramic, Straumann) combined with enamel matrix proteins (Straumann Emdogain, Straumann). Guided bone regeneration (GBR) using autografts (autogenous dental graft), allografts (enCore Combination Allograft...
in phase 4 clinical trials. The clinical trials tend to be registered in the database of their own country, many studies in the U.S. might be registered on ClinicalTrials.gov, but fewer studies in Japan, Australia or Germany, among others, might be registered.

Generally, clinical trials have 4 phases: phases 1–4. Phase 0/early phase 1 has been introduced to assist in eliminating ineffective products early in the development process and is not considered to replace formal phase 1 safety and tolerance studies. Phase 1 trials may involve the first administration to humans, usually to small numbers of healthy volunteers or to patients, in order to test safety and tolerance. If a new treatment is found to be reasonably safe in a phase 1 clinical trial, it can then be tested in a phase 2 clinical trial to find out whether it works. Phase 2 trials may be undertaken in a larger group of human patients to further assess safety and efficacy. Treatments that have been shown to work in phase 2 studies usually must succeed in 1 more phase of testing (phase 3) before they are approved for general use. Phase 3 trials usually involve a large group of patients, in order to compare the safety and effectiveness of the new treatment against the current standard treatment. When a phase 3 clinical trial (or sometimes a phase 2 trial) shows that a new treatment is more effective and/or safer than the current standard one, it can be submitted for approval. Our results indicated a higher ratio of early study phases (early phase 1, phase 1, phase 1/2 and phase 2) in the field of bone regeneration. The periodontal field of application appeared more mature, having more phase 4 studies. In the U.S., more than 47% people ≥ 30 years of age have periodontal disease, and the prevalence increases to 70% among those of ≥ 65 years of age. A similar trend is found in other countries. Since there is a strong need for periodontal treatment, clinical trials in periodontitis might be accelerated.

In general, a new treatment should go through several procedures before it will be approved for therapeutic use. After tests and treatments are assessed in preclinical research, they go through a series of clinical trials in humans. To date, there are no clear reports on comprehensive clinical development trends in specific fields of regenerative medicine using a clinical trial registry. In this study, we focused on bone regeneration in dentistry, especially in dental implantology, based on the data obtained from ClinicalTrials.gov. We used data available on the ClinicalTrials.gov registry as the primary source in order to conduct comprehensive and chronological research, classification and analysis of clinical trials registered in this field, including assessing global research trends in bone regeneration. The clinical trials were conducted all over the world. Although ClinicalTrials.gov is the most global database in the world, there are other data providers. Since clinical trials tend to be registered in the database of their own country, many studies in the U.S. might be registered on ClinicalTrials.gov, but fewer studies in Japan, Australia or Germany, among others, might be registered.

In the next step, we focused on bone regeneration studies in patients requiring dental implant placement. Twenty-four studies were selected through a database search, and 1 study was excluded because the technique was aimed at periimplantitis treatment not bone regeneration. In total, 23 studies were used for the analyses. The number of clinical studies according to study design is shown in Figure 4A. Most of them were interventional studies (21 studies). An overview of the interventional clinical trials on bone regeneration in dental implantology is shown in Table 1. Among these interventional studies, 16 were parallel design randomized controlled trials. Regarding the bone regeneration methods, the major technique examined in interventional clinical trials was GBR (12 studies), followed by alveolar ridge preservation (ARP; 5 studies), and sinus floor elevation (SFE; 3 studies, Fig. 4B). The characteristics of the interventions are shown in Table 2. The results indicated that various grafting materials and procedures were examined to determine clinical efficacy. The grafting materials included autografts (bone marrow-derived cells, dentinal graft and platelet-rich fibrin), allografts (freeze-dried bone allograft, cortico-cancellous allogeneic block [PHOENIX, TBF] and MinerOss [BioHorizons], xenografts [deproteinized bovine bone mineral [Geistlich Bio-Oss]], and alloplasts (biphasic calcium sulfate [BONDBONE, MIS Implant Technologies], calcium phosphosilicate alloplastic bone and nanocrystalline synthetic hydroxyapatite [NanoBone, ARTOSS]). Combinations of these materials were more frequently used (5 studies). The usefulness of membranes was also examined for the GBR and ARP techniques.

**Discussion**

In general, a new treatment should go through several procedures before it will be approved for therapeutic use. After tests and treatments are assessed in preclinical research, they go through a series of clinical trials in humans. To date, there are no clear reports on comprehensive clinical development trends in specific fields of regenerative medicine using a clinical trial registry. In this study, we focused on bone regeneration in dentistry, especially in dental implantology, based on the data obtained from ClinicalTrials.gov. We used data available on the ClinicalTrials.gov registry as the primary source in order to conduct comprehensive and chronological research, classification and analysis of clinical trials registered in this field, including assessing global research trends in bone regeneration. The clinical trials were conducted all over the world. Although ClinicalTrials.gov is the most global database in the world, there are other data providers. Since clinical trials tend to be registered in the database of their own country, many studies in the U.S. might be registered on ClinicalTrials.gov, but fewer studies in Japan, Australia or Germany, among others, might be registered.

Generally, clinical trials have 4 phases: phases 1–4. Phase 0/early phase 1 has been introduced to assist in eliminating ineffective products early in the development process and is not considered to replace formal phase 1 safety and tolerance studies. Phase 1 trials may involve the first administration to humans, usually to small numbers of healthy volunteers or to patients, in order to test safety and tolerance. If a new treatment is found to be reasonably safe in a phase 1 clinical trial, it can then be tested in a phase 2 clinical trial to find out whether it works. Phase 2 trials may be undertaken in a larger group of human patients to further assess safety and efficacy. Treatments that have been shown to work in phase 2 studies usually must succeed in 1 more phase of testing (phase 3) before they are approved for general use. Phase 3 trials usually involve a large group of patients, in order to compare the safety and effectiveness of the new treatment against the current standard treatment. When a phase 3 clinical trial (or sometimes a phase 2 trial) shows that a new treatment is more effective and/or safer than the current standard one, it can be submitted for approval. Our results indicated a higher ratio of early study phases (early phase 1, phase 1, phase 1/2 and phase 2) in the field of bone regeneration. The periodontal field of application appeared more mature, having more phase 4 studies. In the U.S., more than 47% people ≥ 30 years of age have periodontal disease, and the prevalence increases to 70% among those of ≥ 65 years of age. A similar trend is found in other countries. Since there is a strong need for periodontal treatment, clinical trials in periodontitis might be accelerated.
## Trends in clinical trials on bone regeneration

<table>
<thead>
<tr>
<th>Study design</th>
<th>NCT no.</th>
<th>Intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Randomized parallel assignment</td>
<td>NCT00755911</td>
<td>Socket preservation with bone marrow-derived tissue repair cell therapy plus Gelfoam carrier (Pfizer) or only Gelfoam carrier</td>
</tr>
<tr>
<td></td>
<td>NCT00900718</td>
<td>Socket preservation with synthetic bone grafting material (Straumann BoneCeramic) or DBBM(^{\dagger}) (Bio-Oss)</td>
</tr>
<tr>
<td></td>
<td>NCT01012921</td>
<td>GBR(^{\ddagger}) with PEG(^{\dagger\dagger}) membrane (Straumann MembraGel, Straumann) or standard collagen membrane (Bio-Gide)</td>
</tr>
<tr>
<td></td>
<td>NCT01572298</td>
<td>GBR with allograft (MinerOss) alone or with autograft and allograft</td>
</tr>
<tr>
<td></td>
<td>NCT01603693</td>
<td>DBBM (Bio-Oss) alone or in combination with biphasic calcium sulfate (BONDBONE)</td>
</tr>
<tr>
<td></td>
<td>NCT01616953</td>
<td>Alveolar defects secondary to clefts or trauma, autogenous bone grafting or bone marrow-derived cell therapy</td>
</tr>
<tr>
<td></td>
<td>NCT01628367</td>
<td>GBR around dental implants placed in fresh extraction sockets with or without nonresorbable PTFE membrane</td>
</tr>
<tr>
<td></td>
<td>NCT01942304</td>
<td>Sinus augmentation with calcium phosphosilicate alloplastic bone putty or anorganic bovine bone mineral</td>
</tr>
<tr>
<td></td>
<td>NCT02613663</td>
<td>Immediate implant using nanocrystalline hydroxyapatite (Nano-Bone) or autogenous bone</td>
</tr>
<tr>
<td></td>
<td>NCT03179683</td>
<td>Bilateral sinus lift and simultaneous dental implant placement with diode laser application</td>
</tr>
<tr>
<td></td>
<td>NCT03302143</td>
<td>GBR with autogenous bone and DBBM (Bio-Oss) or GBR with freeze-dried bone allograft</td>
</tr>
<tr>
<td></td>
<td>NCT03432702</td>
<td>Horizontal ridge augmentation using GBR with or without autogenous block graft</td>
</tr>
<tr>
<td></td>
<td>NCT03785717</td>
<td>Horizontal guide bone regeneration with or without shock waves</td>
</tr>
<tr>
<td></td>
<td>NCT03946020</td>
<td>GBR with DBBM (Bio-Oss) in combination with autogenous bone or DBBM alone</td>
</tr>
<tr>
<td></td>
<td>NCT04131894</td>
<td>Socket preservation with autogenous dentinal graft or mixture of PRF(^{\dagger\dagger}) and autogenous dentinal graft or empty as control</td>
</tr>
<tr>
<td></td>
<td>NCT04133090</td>
<td>Injectable PRF-enriched allograft material or autogenous block bone graft</td>
</tr>
<tr>
<td>Randomized sequential assignment</td>
<td>NCT03290638</td>
<td>Socket preservation with dehydrated human amnion–chorion membrane or type I bovine collagen membrane</td>
</tr>
</tbody>
</table>

*Table 1 → continues on the next page*
### Study design

<table>
<thead>
<tr>
<th>Study design</th>
<th>NCT† no.</th>
<th>Intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonrandomized parallel assignment</td>
<td>NCT00163605</td>
<td>Sinus lift procedures with bone substitute macroporous biphasic calcium phosphate fibrin sealant vapor-heated solvent/detergent treated 4 IU/mL thrombin</td>
</tr>
<tr>
<td></td>
<td>NCT03357705</td>
<td>Alveolar ridge preservation with nanocrystalline synthetic hydroxyapatite or bovine collagen sponge</td>
</tr>
<tr>
<td>Single-group assignment</td>
<td>NCT03076138</td>
<td>Gene-activated bone substitute consisting of octacalcium phosphate and plasmid DNA encoding VEGF§§ for maxillofacial bone regeneration</td>
</tr>
<tr>
<td></td>
<td>NCT03879967</td>
<td>Alveolar ridge augmentation with cortico-cancellous allogeneic blocks (PHOENIX) and autogenous chips and demineralized bovine bone (Bio-Oss)</td>
</tr>
</tbody>
</table>

† DBBM = deproteinized bovine bone mineral.
†† PEG = polyethylene glycol.
§§ VEGF = vascular endothelial growth factor.

### Table 1: Overview of clinical trials on bone regeneration in dental implantology.

<table>
<thead>
<tr>
<th>Graft type</th>
<th>GBR†</th>
<th>ARP‡</th>
<th>SFE§</th>
<th>Others</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autografts</td>
<td>1</td>
<td>2</td>
<td>–</td>
<td>1</td>
</tr>
<tr>
<td>Allografts</td>
<td>1</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Alloplasts</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>–</td>
</tr>
<tr>
<td>Autografts + allografts</td>
<td>2</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Autografts + xenografts</td>
<td>1</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Xenografts + alloplasts</td>
<td>1</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Autografts + allografts + xenografts</td>
<td>1</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Membranes</td>
<td>2</td>
<td>1</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Others</td>
<td>2</td>
<td>–</td>
<td>1</td>
<td>–</td>
</tr>
</tbody>
</table>

† GBR = guided bone regeneration.
‡ ARP = alveolar ridge preservation.
§ SFE = sinus floor elevation.

### Table 2: Characteristics of interventions.
A randomized controlled clinical trial is a study design that uses control patients who receive no treatment, the conventional treatment or a placebo. Randomization is the best way of ensuring that the results of trials are not biased by the way participants in each group are selected, so randomized controlled trials are the most reliable way to compare treatments. In this study, of the 23 trials on bone regeneration in dental implantology screened, 21 studies were interventional studies, 17 of which employed randomized assignment. The results indicated that the rate of randomized assignment was high (73.9%) in dental implantology studies.

Loss of bone width and depth can affect how successful the implant will be. In order to regenerate adequate bone volume for dental implant placement, the GBR technique is often performed. Most studies aiming for lateral bone augmentation have used the principles of GBR by combining different bone grafts and barrier membranes.4 However, the ideal graft or membrane material remains unclear.4 The results of our study indicated that 57% of interventional clinical trials on bone regeneration in dental implantology (12 studies) used the GBR technique. Most studies on GBR treatment (41.7%) combined different bone grafts: autografts and allografts; autografts and xenografts; xenografts and alloplasts; and autografts, allografts and xenografts.

In humans, approximately 50% of the bone volume is lost after tooth extraction during the first year.10,11 The alveolar bone resorption may not allow optimal positioning of dental implants.12,13 Maxillary sinus floor augmentation via SFE is a surgical procedure to gain the bone mass required in order to place dental implants. There is consensus that some threshold of osseous deficiency, vertical, horizontal or both, exists at a site where a sinus bone graft is required for successful implant treatment regardless of residual bone quality.14 Although this procedure is considered safe, various complications may arise during or after the surgery, such as perforation of the sinus membrane.15 ARP is performed after tooth extraction in an attempt to maintain the alveolar ridge height and width. ARP is a less invasive technique than SFE. The results of this study showed that the start dates of SFE clinical trials were from 2004 to 2013, whereas those of ARP studies were from 2006 to 2017. These results indicated a shift from SFE to ARP for bone regeneration in dental implantology.

In this study, we utilized the most global clinical trial database, ClinicalTrials.gov, to capture the largest trends in bone regeneration studies in dental implantology. The limitation of this study is that registered trials make up only a part of all existing trials. It has been suggested that only 50% of clinical studies indexed in PubMed that involved administration of cells for regenerative medicine indicated any clinical trial identifier.16 In addition, since ClinicalTrials.gov does not provide comprehensive results of clinical trials, it is impossible to analyze the results of the trials themselves.

**Conclusion**

In conclusion, these results on clinical trials registered on the ClinicalTrials.gov registration site showed the global trends in clinical trials on bone regeneration in implant dentistry. ClinicalTrials.gov, a publicly accessible database, is useful for detailed characterization and analysis of clinical trials. This study revealed that the periodontal field of application was more accelerated, having more phase 4 studies. As for implant dentistry, the most frequently conducted study was the randomized clinical trials of GBR technique using combination of different bone grafts materials. The present study has potential implications for understanding the clinical trends in the development of therapeutic bone regeneration techniques in dental implantology. In the future, further studies would be needed for further development of an innovative therapy in dental implant treatment.

**Competing interests**

The authors declare that they have no competing interests.

**Figure legends**

Fig. 1 – The number of clinical trials on bone regeneration in dentistry according to country.

Fig. 2 – The number of clinical trials on bone regeneration in dentistry according to start year. The current status of the studies is also color-coded.

Fig. 3 – Phases of clinical trials on bone regeneration in dentistry.

Fig. 4 – Study design (A) and bone regeneration method (B) of clinical trials on bone regeneration in dental implantology.
dental implantology. GBR = guided bone regeneration; ARP = alveolar ridge preservation; SFE = sinus floor elevation.

References


